000288729 001__ 288729
000288729 005__ 20250815105245.0
000288729 0247_ $$2doi$$a10.1016/j.ebiom.2024.105024
000288729 0247_ $$2pmid$$apmid:38412638
000288729 0247_ $$2altmetric$$aaltmetric:160114665
000288729 037__ $$aDKFZ-2024-00438
000288729 041__ $$aEnglish
000288729 082__ $$a610
000288729 1001_ $$aHarewood, Rhea$$b0
000288729 245__ $$aAssociation between pre-diagnostic circulating lipid metabolites and colorectal cancer risk: a nested case-control study in the European Prospective Investigation into Cancer and Nutrition (EPIC).
000288729 260__ $$aAmsterdam [u.a.]$$bElsevier$$c2024
000288729 3367_ $$2DRIVER$$aarticle
000288729 3367_ $$2DataCite$$aOutput Types/Journal article
000288729 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1709131996_765
000288729 3367_ $$2BibTeX$$aARTICLE
000288729 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000288729 3367_ $$00$$2EndNote$$aJournal Article
000288729 520__ $$aAltered lipid metabolism is a hallmark of cancer development. However, the role of specific lipid metabolites in colorectal cancer development is uncertain.In a case-control study nested within the European Prospective Investigation into Cancer and Nutrition (EPIC), we examined associations between pre-diagnostic circulating concentrations of 97 lipid metabolites (acylcarnitines, glycerophospholipids and sphingolipids) and colorectal cancer risk. Circulating lipids were measured using targeted mass spectrometry in 1591 incident colorectal cancer cases (55% women) and 1591 matched controls. Multivariable conditional logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for associations between concentrations of individual lipid metabolites and metabolite patterns with colorectal cancer risk.Of the 97 assayed lipids, 24 were inversely associated (nominally p < 0.05) with colorectal cancer risk. Hydroxysphingomyelin (SM (OH)) C22:2 (ORper doubling 0.60, 95% CI 0.47-0.77) and acylakyl-phosphatidylcholine (PC ae) C34:3 (ORper doubling 0.71, 95% CI 0.59-0.87) remained associated after multiple comparisons correction. These associations were unaltered after excluding the first 5 years of follow-up after blood collection and were consistent according to sex, age at diagnosis, BMI, and colorectal subsite. Two lipid patterns, one including 26 phosphatidylcholines and all sphingolipids, and another 30 phosphatidylcholines, were weakly inversely associated with colorectal cancer.Elevated pre-diagnostic circulating levels of SM (OH) C22:2 and PC ae C34:3 and lipid patterns including phosphatidylcholines and sphingolipids were associated with lower colorectal cancer risk. This study may provide insight into potential links between specific lipids and colorectal cancer development. Additional prospective studies are needed to validate the observed associations.World Cancer Research Fund (reference: 2013/1002); European Commission (FP7: BBMRI-LPC; reference: 313010).
000288729 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000288729 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000288729 650_7 $$2Other$$aAcylcarnitines
000288729 650_7 $$2Other$$aColorectal cancer
000288729 650_7 $$2Other$$aGlycerophospholipids
000288729 650_7 $$2Other$$aLipids
000288729 650_7 $$2Other$$aMetabolomics
000288729 650_7 $$2Other$$aSphingolipids
000288729 7001_ $$aRothwell, Joseph A$$b1
000288729 7001_ $$aBešević, Jelena$$b2
000288729 7001_ $$aViallon, Vivian$$b3
000288729 7001_ $$aAchaintre, David$$b4
000288729 7001_ $$aGicquiau, Audrey$$b5
000288729 7001_ $$aRinaldi, Sabina$$b6
000288729 7001_ $$aWedekind, Roland$$b7
000288729 7001_ $$aPrehn, Cornelia$$b8
000288729 7001_ $$aAdamski, Jerzy$$b9
000288729 7001_ $$aSchmidt, Julie A$$b10
000288729 7001_ $$aJacobs, Inarie$$b11
000288729 7001_ $$aTjønneland, Anne$$b12
000288729 7001_ $$aOlsen, Anja$$b13
000288729 7001_ $$aSeveri, Gianluca$$b14
000288729 7001_ $$0P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aKaaks, Rudolf$$b15$$udkfz
000288729 7001_ $$0P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4$$aKatzke, Verena$$b16$$udkfz
000288729 7001_ $$aSchulze, Matthias B$$b17
000288729 7001_ $$aPrada, Marcela$$b18
000288729 7001_ $$aMasala, Giovanna$$b19
000288729 7001_ $$aAgnoli, Claudia$$b20
000288729 7001_ $$aPanico, Salvatore$$b21
000288729 7001_ $$aSacerdote, Carlotta$$b22
000288729 7001_ $$aJakszyn, Paula Gabriela$$b23
000288729 7001_ $$aSánchez, Maria-Jose$$b24
000288729 7001_ $$aCastilla, Jesús$$b25
000288729 7001_ $$aChirlaque, María-Dolores$$b26
000288729 7001_ $$aAtxega, Amaia Aizpurua$$b27
000288729 7001_ $$avan Guelpen, Bethany$$b28
000288729 7001_ $$aHeath, Alicia K$$b29
000288729 7001_ $$aPapier, Keren$$b30
000288729 7001_ $$aTong, Tammy Y N$$b31
000288729 7001_ $$aSummers, Scott A$$b32
000288729 7001_ $$aPlaydon, Mary$$b33
000288729 7001_ $$aCross, Amanda J$$b34
000288729 7001_ $$aKeski-Rahkonen, Pekka$$b35
000288729 7001_ $$aChajès, Véronique$$b36
000288729 7001_ $$aMurphy, Neil$$b37
000288729 7001_ $$aGunter, Marc J$$b38
000288729 773__ $$0PERI:(DE-600)2799017-5$$a10.1016/j.ebiom.2024.105024$$gVol. 101, p. 105024 -$$p105024$$tEBioMedicine$$v101$$x2352-3964$$y2024
000288729 8564_ $$uhttps://inrepo02.dkfz.de/record/288729/files/1-s2.0-S2352396424000598-main.pdf
000288729 8564_ $$uhttps://inrepo02.dkfz.de/record/288729/files/1-s2.0-S2352396424000598-main.pdf?subformat=pdfa$$xpdfa
000288729 909CO $$ooai:inrepo02.dkfz.de:288729$$pVDB
000288729 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aDeutsches Krebsforschungszentrum$$b15$$kDKFZ
000288729 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4$$aDeutsches Krebsforschungszentrum$$b16$$kDKFZ
000288729 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000288729 9141_ $$y2024
000288729 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEBIOMEDICINE : 2022$$d2023-08-26
000288729 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-26
000288729 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-26
000288729 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-08-26
000288729 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-05-02T08:51:17Z
000288729 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-05-02T08:51:17Z
000288729 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-05-02T08:51:17Z
000288729 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-26
000288729 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-08-26
000288729 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-26
000288729 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-08-26
000288729 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bEBIOMEDICINE : 2022$$d2023-08-26
000288729 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-08-26
000288729 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-08-26
000288729 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000288729 980__ $$ajournal
000288729 980__ $$aVDB
000288729 980__ $$aI:(DE-He78)C020-20160331
000288729 980__ $$aUNRESTRICTED